Synendos Therapeutics AG

At Synendos, we develop a new class of small molecules for the treatment of anxiety and stress-related disorders. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need. Selective Endocannabinoid Reuptake Inhibitors (SERIs) restore the normal functioning of the endocannabinoid system by hitting an as-yet unprecedented drug target. Anxiety and stress related diseases are characterized by endocannabinoid deficiency and SERIs exert therapeutic effects by restoring the physiological concentration of endocannabinoids and reactivating the normal functioning of the endocannabinoid system.